On Target Laboratories

Executive Summary

On Target Laboratories is a biotechnology company focused on advancing precision cancer surgery through its proprietary intraoperative molecular imaging technology. The company's lead product, CYTALUX® (pafolacianine), is an FDA-approved optical imaging agent that illuminates cancer tissue in real-time during surgery, enabling surgeons to achieve more complete tumor resections. By targeting folate receptors overexpressed on many cancer cells, CYTALUX provides a clear visual distinction between malignant and healthy tissue, addressing a critical need in oncology surgery. Founded in 2011 and based in West Lafayette, Indiana, the company has established a strong foothold in the emerging field of fluorescence-guided surgery.

Upcoming Catalysts (preview)

• H2 2026European Union marketing authorization for CYTALUX70% success
• H1 2026Initiation of pivotal trial for CYTALUX in additional cancer indications (e.g., ovarian, lung)50% success
• H2 2026Announcement of strategic partnership or licensing deal for ex-U.S. commercialization60% success